Transplant diagnostics developer Verici Dx (LSE:VRCI) has completed its placing and WRAP retail offer, raising £8.75 million gross, after shareholders approved the resolutions at a general meeting on 27 October 2026.
What was announced
Verici Dx (LSE:VRCI) plc, the AIM-quoted developer of clinical diagnostics for organ transplantation, confirmed on 30 October 2026 that its placing and WRAP retail offer had completed. The fundraising generated gross proceeds of £8.75 million and net proceeds of £8.13 million, according to the announcement.
The company said shareholders passed the resolutions needed for the fundraising at its general meeting on Tuesday 27 October 2026. It also stated that 2,691,999,983 new ordinary shares of 0.1 pence each had been admitted to trading on AIM. The shares carry the ISIN GB00BM8HZD43.
Capitalised terms in the announcement refer to a circular published on 10 August 2026, which set out the full terms of the fundraising. That circular was not reproduced in the completion notice.
The numbers
The completion notice does not restate the placing price in its main text, but the accompanying director dealing notifications record a price of 0.2 pence per share. On that basis, by calculation, gross proceeds of £8.75 million would correspond to roughly 4.375 billion new shares in total. That figure is higher than the 2,691,999,983 shares referred to as admitted in this announcement. The notice does not explain the difference, and it does not break down how many shares were issued under the placing and how many under the WRAP retail offer. The total number of shares in issue and total voting rights following admission were also not stated.
The cost of the fundraising, by calculation from the gross and net figures, was approximately £620,000, or about 7% of gross proceeds.
The announcement does not set out a use of proceeds, a discount to the prevailing share price, or management commentary. Those details, if any, would be found in the August circular.
Director participation
Two board members took part in the placing on 28 October 2026, both through off-market transactions at 0.2 pence per share.
Non-executive chairman Julian Baines subscribed for 10,000,000 shares, worth £20,000 by calculation. His holding rose from 8,548,482 shares to 18,548,482 shares. Because of the much larger share count after the fundraising, his percentage interest fell from 0.37% to 0.28%.
Chief executive Sara Barrington subscribed for 5,000,000 shares, worth £10,000 by calculation. Her holding rose from 8,285,715 shares to 13,285,715 shares, with her percentage interest falling from 0.36% to 0.20%.
Taken together, the two directors' percentage figures point to a substantial increase in the company's issued share capital, consistent with the scale of a fundraising at a sub-penny price. The precise enlarged share Capital was not disclosed in the text reviewed.
Background
Verici Dx (LSE:VRCI) describes itself as a developer of advanced clinical diagnostics for organ transplant. Its advisers on the transaction are Singer Capital Markets, which acts as nominated adviser and joint broker, and Oberon Capital as joint broker. Walbrook PR handles media and investor relations.
The use of a WRAP retail offer alongside the institutional placing allowed private investors to participate at the same price as institutions. The resolutions passed on 27 October were required to give the directors authority to allot the new shares.
What to watch next
The announcement contains no statement on next steps. Investors are likely to look for a total voting rights notice confirming the enlarged share capital, and for any operational or commercial update explaining how the £8.13 million of net proceeds will be deployed. Any further detail on the split between the placing and the retail offer, and on whether further share admissions are due, would also help clarify the share count. No timetable for such updates was given.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...